This January Abrocitinib (CIBINQO) received approval by the FDA as an oral drug for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. It indicates for patients who didn't have relief with current systemic drugs.

Abrocitinib acts as a selective inhibitor of Janus kinase 1 (JAK1).

Viloxazine contains 7H-pyrrolo[2,3-d]pyrimidine moiety in its backbone.

We have made a set of Building Blocks, which contain such parts – the perfect start for your research!